Clinical trial DESTINY-GASTRIC-05
A multicenter, randomized, open-label, phase 3 trial of trastuzumab deruxtecan (ENHERTU(r)) plus chemotherapy plus or minus pembrolizumab versus chemotherapy plus trastuzumab plus or minus pembrolizumab as first-line treatment in participants with unresectable, locally advanced or metastatic her2-positive gastric or gastroesophageal junction (GEJ) cancer DS8201-724 / DESTINY-GASTRIC-05
| Cancers | |
|---|---|
| Organ | Stomach - Duodenum-esogastric junction |
| Trial status | Trial open for recruitment |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Daiichi Sankyo |
| EudraCT Identifier | 2024-513122-27-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06731478 |
| Last update |